2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Calaspargase pegol-mknl

Trial Locations (2)

Greenebaum Cancer Center, University of Maryland Medical Systems, Baltimore

West Virginia University, Morgantown

All Listed Sponsors

lead

West Virginia University

OTHER